-DOCSTART- -X- O
Abstract -X- _ O
The -X- _ O
recent -X- _ O
identification -X- _ O
of -X- _ O
a -X- _ O
novel -X- _ O
human -X- _ O
coronavirus -X- _ O
responsible -X- _ O
of -X- _ O
a -X- _ O
SARS-like -X- _ O
illness -X- _ O
in -X- _ O
the -X- _ O
Middle-East -X- _ O
a -X- _ O
decade -X- _ O
after -X- _ O
the -X- _ O
SARS -X- _ O
pandemic -X- _ O
, -X- _ O
demonstrates -X- _ O
that -X- _ O
reemergence -X- _ O
of -X- _ O
a -X- _ O
SARS-like -X- _ O
coronavirus -X- _ O
from -X- _ O
an -X- _ O
animal -X- _ O
reservoir -X- _ O
remains -X- _ O
a -X- _ O
credible -X- _ O
threat. -X- _ O
Because -X- _ O
SARS -X- _ O
is -X- _ O
contracted -X- _ O
by -X- _ O
aerosolized -X- _ O
contamination -X- _ O
of -X- _ O
the -X- _ O
respiratory -X- _ O
tract -X- _ O
, -X- _ O
a -X- _ O
vaccine -X- _ O
inducing -X- _ O
mucosal -X- _ O
long-term -X- _ O
protection -X- _ O
would -X- _ O
be -X- _ O
an -X- _ O
asset -X- _ O
to -X- _ O
control -X- _ O
new -X- _ O
epidemics. -X- _ O
To -X- _ O
this -X- _ O
aim -X- _ O
, -X- _ O
we -X- _ O
generated -X- _ O
live -X- _ B-Intervention
attenuated -X- _ I-Intervention
recombinant -X- _ I-Intervention
measles -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
MV -X- _ I-Intervention
) -X- _ I-Intervention
candidates -X- _ O
expressing -X- _ O
either -X- _ O
the -X- _ O
membrane-anchored -X- _ O
SARS-CoV -X- _ O
spike -X- _ O
( -X- _ O
S -X- _ O
) -X- _ O
protein -X- _ O
or -X- _ O
its -X- _ O
secreted -X- _ O
soluble -X- _ O
ectodomain -X- _ O
( -X- _ O
Ssol -X- _ O
) -X- _ O
. -X- _ O
In -X- _ O
mice -X- _ B-Patient
susceptible -X- _ I-Patient
to -X- _ I-Patient
measles -X- _ I-Patient
virus -X- _ I-Patient
, -X- _ O
recombinant -X- _ B-Outcome
MV -X- _ I-Outcome
expressing -X- _ I-Outcome
the -X- _ I-Outcome
anchored -X- _ I-Outcome
full-length -X- _ I-Outcome
S -X- _ I-Outcome
induced -X- _ I-Outcome
the -X- _ I-Outcome
highest -X- _ I-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
and -X- _ I-Outcome
fully -X- _ I-Outcome
protected -X- _ I-Outcome
immunized -X- _ I-Outcome
animals -X- _ I-Outcome
from -X- _ I-Outcome
intranasal -X- _ I-Outcome
infectious -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
SARS-CoV. -X- _ I-Outcome
As -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
immunization -X- _ I-Outcome
with -X- _ I-Outcome
adjuvanted -X- _ I-Outcome
recombinant -X- _ I-Outcome
Ssol -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ I-Outcome
recombinant -X- _ I-Outcome
MV -X- _ I-Outcome
induced -X- _ I-Outcome
stronger -X- _ I-Outcome
and -X- _ I-Outcome
Th1-biased -X- _ I-Outcome
responses -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
hallmark -X- _ I-Outcome
of -X- _ I-Outcome
live -X- _ I-Outcome
attenuated -X- _ I-Outcome
viruses -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
highly -X- _ I-Outcome
desirable -X- _ I-Outcome
feature -X- _ I-Outcome
for -X- _ I-Outcome
an -X- _ I-Outcome
antiviral -X- _ I-Outcome
vaccine -X- _ I-Outcome
. -X- _ O

